Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  IGI LABORIGI       

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 88,6 M
EBIT 2017 12,2 M
Net income 2017 -0,72 M
Debt 2017 72,1 M
Yield 2017 -
Sales 2018 128 M
EBIT 2018 27,0 M
Net income 2018 12,0 M
Debt 2018 70,4 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 46,50
EV / Sales2017 6,40x
EV / Sales2018 4,42x
Capitalization 495 M
More Financials
Company
Teligent, Inc. develops, manufactures and markets topical formulations.The company sells generic topical pharmaceutical products under IGI label.It also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter and cosmetic markets.The company's products... 
Sector
Pharmaceuticals
Calendar
07/27Earnings Release
More about the company
Surperformance© ratings of IGI LABORIGI
Trading Rating : Investor Rating :
More Ratings
Latest news on IGI LABORIGI
05/26 TELIGENT : Commerce Bank Has $145,000 Stake in Teligent Inc
05/24 TELIGENT, INC. (NASDAQ : TLGT) Files An 8-K Submission of Matters to a Vote of S..
05/24 TELIGENT, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
05/16 TELIGENT, INC. : To Present At Bank Of America Merrill Lynch Healthcare Conferen..
05/10 TELIGENT, INC. (NASDAQ : TLGT) Files An 8-K Results of Operations and Financial ..
05/10 TELIGENT : Results of Operations and Financial Condition, Financial Statements a..
05/10 TELIGENT : Management's Discussion and Analysis of Financial Condition and Resul..
05/03 TELIGENT, INC. : To Present At Deutsche Bank 42nd Annual Health Care Conference ..
05/03 TELIGENT : tops 1Q profit forecasts
05/02 TELIGENT, INC. : Results of Operations and Financial Condition, Financial Statem..
More news
Sector news : Pharmaceuticals - NEC
09:22a COVESTRO : vows to cash out to shareholders if no takeover on cards
04:55a MYLAN : Investors call on Mylan chairman, director to step down
06/28 UK blue chips led lower by Hargreaves as strong pound takes toll
06/28DJVECTURA : In Asthma Collaboration With Novartis's Sandoz
06/28DJGLAXOSMITHKLINE : Announces US Filing For Mepolizumab
More sector news : Pharmaceuticals - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 9,75 $
Spread / Average Target 4,8%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jason Grenfell-Gardner President, Chief Executive Officer & Director
James Charles Gale Chairman
Jenniffer L. Collins CFO, Secretary & Head-Investor Relations
Stephen Richardson Chief Scientific Officer
Nadya Lawrence Senior Vice President-Technical Services
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IGI LABORIGI495
JOHNSON & JOHNSON17.19%360 489
ROCHE HOLDING LTD.8.34%226 454
NOVARTIS11.74%223 476
PFIZER3.91%200 985
MERCK AND COMPANY10.68%178 223
More Results